Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)

MONTPELLIER, France–(BUSINESS WIRE)–Medincell (Paris:MEDCL) Medincell will host Investor webcast today to discuss the implications of the approval for the Company and answer questions from analysts.   Webcast Details Date: Friday, October 9, 2026 Time: 4:00 p.m. CEST / 10:00 a.m. ET Webcast: https://www.medincell.com/investor-webcast-oct-9-2026/ A replay of the webcast will be available on Medincell’s website following the event. Medincell (Euronext: MEDCL) achieves major milestone with the a

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.